The global small cell lung cancer therapeutics market size is estimated at USD 6.46 billion in 2024, grew to USD 7.25 billion in 2025 and is predicted to surpass around USD 20.6 billion by 2034, expanding at a CAGR of 12.30% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Small Cell Lung Cancer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Small Cell Lung Cancer Therapeutics Market, by Therapy Type, 2024-2034
8.1.1. Immunotherapy
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Targeted Therapy
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Chemotherapy
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Small Cell Lung Cancer Therapeutics Market, by Drug Type, 2024-2034
9.1.1. Atezolizumab
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Topotecan
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Lurbinectedin
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Durvalumab
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Methotrexatepo side
9.1.5.1. Market Revenue and Forecast (2021-2034)
9.1.6. Pembrolizumab
9.1.6.1. Market Revenue and Forecast (2021-2034)
10.1. Small Cell Lung Cancer Therapeutics Market, by Route of Administration, 2024-2034
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2021-2034)
11.1. Small Cell Lung Cancer Therapeutics Market, by Distribution Channel, 2024-2034
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast (2021-2034)
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.1.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.1.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.2.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.2.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.3.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.3.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.4.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.4.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.5.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Drug Type (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2034)
13.1. F. Hoffmann-La Roche Ltd.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Mylan N.V
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Teva Pharmaceutical Industries Ltd.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sanofi
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Merck & Co., Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Sun Pharmaceutical Industries Ltd.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Aurobindo Pharma
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Lupin
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. CLOVIS ONCOLOGY
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Johnson & Johnson Private Limited
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample